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CORRECTION
Correction to: Secukinumab Versus Adalimumab
for Psoriatic Arthritis: Comparative Effectiveness
up to 48 Weeks Using a Matching-Adjusted Indirect
Comparison
Peter Nash . Iain B. McInnes . Philip J. Mease . Howard Thom .
Matthias Hunger . Andreas Karabis . Kunal Gandhi . Shephard Mpofu .
Steffen M. Jugl
 The Author(s) 2018
Correction to: Rheumatol Ther (2018) 5:99–122
https://doi.org/10.1007/s40744-018-0106-6
Under Methods section, heading Analyses:
Pairwise Comparisons, one of the probability
value was published incorrectly in a sentence.
The correct sentence should read as follows:
In acknowledgment of the recent American
Statistical Association statement on P values
and their preference to avoid such a threshold
in clinical research [39, 40], our data were also
analyzed using a more modern definition of the
strength of evidence that P values can provide
[41, 42] (0.1[P[0.001 as increasing evidence,
P B 0.001 as strong evidence against the null
hypothesis; Table S8 in the supplementary
material).
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